William Blair analyst Matt Larew has maintained their bullish stance on DHR stock, giving a Buy rating on July 18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Larew has given his Buy rating due to a combination of factors including Danaher’s strong second-quarter performance, which slightly exceeded expectations. The company’s total revenue surpassed both the firm’s and consensus estimates, driven by robust growth in biotechnology core revenue and a notable increase in bioprocessing revenues. Additionally, the diagnostics segment showed positive growth, particularly in nonrespiratory Cepheid products.
Furthermore, Danaher reiterated its guidance for core growth and slightly raised its full-year EPS expectations, reflecting confidence in its ongoing performance. The company anticipates continued growth in its biotechnology segment and a favorable foreign exchange impact, which is now expected to be a tailwind. These positive indicators contribute to Larew’s optimistic outlook and support his Buy recommendation for Danaher’s stock.
In another report released on July 18, Robert W. Baird also maintained a Buy rating on the stock with a $226.00 price target.